WO2002049413A2 - Thrombopoietin mimetics - Google Patents

Thrombopoietin mimetics Download PDF

Info

Publication number
WO2002049413A2
WO2002049413A2 PCT/US2001/050774 US0150774W WO0249413A2 WO 2002049413 A2 WO2002049413 A2 WO 2002049413A2 US 0150774 W US0150774 W US 0150774W WO 0249413 A2 WO0249413 A2 WO 0249413A2
Authority
WO
WIPO (PCT)
Prior art keywords
thiosemicarbazide
carboxyphenyl
hydroxy
hydroxybenzylidene
substituted
Prior art date
Application number
PCT/US2001/050774
Other languages
French (fr)
Other versions
WO2002049413A3 (en
Inventor
Kevin J. Duffy
Juan I. Luengo
Stephen G. Miller
Julian Jenkins
Alan T. Price
Antony N. Shaw
Original Assignee
Smithkline Beecham Corporation
Ligand Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Ligand Pharmaceuticals filed Critical Smithkline Beecham Corporation
Priority to US10/451,300 priority Critical patent/US7241783B2/en
Priority to AU2002239718A priority patent/AU2002239718A1/en
Priority to JP2002550771A priority patent/JP2004520302A/en
Priority to EP01987514A priority patent/EP1349613A4/en
Priority to CA002436288A priority patent/CA2436288A1/en
Publication of WO2002049413A2 publication Critical patent/WO2002049413A2/en
Publication of WO2002049413A3 publication Critical patent/WO2002049413A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • TPO thrombopoietin
  • Thrombopoietin is a 332-amino acid glycosylated polypeptide which plays a key role in the regulation of megakaryocytopoiesis, the process in which platelets are produced from bone marrow megakaryocytes.
  • TPO Thrombopoietin
  • TPO is produced in the liver but exerts its main function in the bone marrow, where it stimulates the differentiation of stem cells into megakaryocyte progenitors as well as megakaryocyte proliferation, polyploidization and, ultimately, their fragmentation into circulating platelet bodies.
  • TPO is also the primary regulator of situations involving thrombocytopenia and has been shown in a number of studies to increase platelet counts, increase platelet size, and increase isotope incorporation into platelets of recipient animals. See, e.g., Metcalf Nature 369:519-520 (1994).
  • TPO is thought to affect megakaryocytopoiesis in several ways: (1) it produces increases in megakaryocyte size and number; (2) it produces an increase in DNA content, in the form of polyploidy, in megakaryocytes; (3) it increases megakaryocyte endomitosis; (4) it produces increased maturation of megakaryocytes; and (5) it produces an increase in the percentage of precursor cells, in the form of small acetylcholinesterase- positive cells, in the bone marrow.
  • TPO has potential useful application in both the diagnosis and the treatment of various hematological disorders, for example, diseases primarily due to platelet defects.
  • TPO has potential application in the treatment of thrombocytopenic conditions, especially those derived from chemotherapy, radiation therapy, or bone marrow transplantation as treatment for cancer or lymphoma. Indeed, ongoing clinical trials in cancer patients have shown that recombinant human TPO is effective in decreasing the platelet nadir and enhancing platelet recovery when given with high-dose carboplatin chemotherapy. See Basser Blood, 1997, 89: 3118.
  • peg-MGDF pegylated megakaryocyte differentiation factor
  • TPO mimetic Because the slow recovery of platelet levels in patients suffering from thrombocytopenia is a serious problem, it would be desirable to provide compounds which allow for the treatment of thrombocytopenia by acting as a TPO mimetic.
  • TPO peptide mimetics A few years ago, the development of TPO peptide mimetics was reported (WO 96/4018, WO 96/40750, WO 98/25965). These peptides were designed to bind and activate the TPO-R but have no sequence homology to the natural TPO. In recent years, a number of small-molecule agents with TPO mimetic activity been reported.
  • This invention relates to compounds of Formula (I):
  • R! is aryl, optionally substituted with 1 or more substituents selected from Ci- lOalkyl, aryl, heteroaryl, halogen, -C(0)OR 7 , -CONR 7 R 8 , -S(0) n R 6 , - S(0)2NR'R°, sulfonyloxy, nitro, optionally substituted amino, hydroxy, alkoxy;
  • R is selected from hydrogen, Ci _ ⁇ 2alkyl, aryl, substituted aryl, and alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryl, substituted aryl, amino, N-acylamino, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, -C(0)OR 7 , -S(0) 2 NR 7 R 8 , -S(0) n R 6 , aryloxy, nitro, cyano, halogen, and protected -OH, where
  • R° is selected from hydrogen, alkyl, cycloalkyl, CJ-CJ 2 ar yl > substituted alkyl, substituted cycloalkyl and substituted Cj-C ⁇ aryl
  • R' and R° are independently selected from hydrogen, cycloalkyl, aryl, substituted cycloalkyl, substituted aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -C(0)OR", -S(0) n R°, - C(0)NR 6 R 6 , -S(0)2NR 6 R 6 , nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, C ⁇ -Ci2 ar yl > substituted C j-Cj 2aryl and protected -OH where R" is as described above; n is 0-3;
  • Z is selected from S or NR where R 2 is as defined above;
  • R3 is selected from hydrogen, C j -C j galkyl, phenyl, substituted phenyl, carboxyl or C i -C j galkoxy carbony 1 ;
  • L is naphthyl or a group of formula (L):
  • Y is selected from -S, -O and -NRl ⁇ ; where R ⁇ is selected from hydrogen, C ⁇ - Cjoalkyl, substituted Cj-Cjoalkyl, Cj-Cgalkylphenyl, substituted C j - Cgalkylphenyl, is Cj- C ⁇ oalkyl, substituted C;[-C ⁇ oalkyl, CJ-CT 2 ryl or substituted C j -C ⁇ aryl; and
  • X is selected from -SR 16 , -OR 16 or -NHR 17 ; where R 16 is hydrogen, C ⁇ C ⁇ a-kyl or substituted C T -C j ⁇ alkyl; R!7 is hydrogen, C j -Ci ⁇ alkyl, substituted C j -Cioalkyl, C ⁇ -Cgalkylphenyl, Ci-
  • This invention relates to a method of treating thrombocytopenia, which comprises administering to a subject in need thereof an effective amount of a TPO mimetic compound of Formula (I).
  • the present invention also relates to the discovery that the compounds of Formula (I) are active as agonists of the TPO receptor.
  • compositions comprising a pharmaceutical carrier and compounds useful in the methods of the invention.
  • Also included in the present invention are methods of co-administering the presently invented TPO mimetic compounds with further active ingredients.
  • Formula I compounds are those in which R S Cj-C ⁇ aryl, particularly phenyl, substituted with a carboxy or sulfonic acid substituent.
  • Formula I compounds are those in which R1 and R**-* are independently selected from hydrogen, C ⁇ .i Q alkyl, C j _i2 a ryl and substituted C ⁇ _ ⁇ 2aryl.
  • Z is S or -NR 2 where R 2 is as defined above;
  • L is C3-Cgaryl optionally substituted with form 1 to 3 substituents selected from the group consisting of: hydroxy, nitro, -C(0)OH, alkyl, substituted alkyl, C _
  • X is -OH or methoxy; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
  • Rl is phenyl, substituted with either carboxylic acid or sulfonic acid
  • Z, R****, R , L, X and Y are as described in claim 1 ; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
  • R ⁇ L, X are as described in claim 1; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
  • L is selected from 3-biphenyl , 4-biphenyl or 1-N-phenylpyrazole substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F;
  • R 1 , R 2 , R 3 and Y are as described in claim 1; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
  • X is selected from 3-carboxylic acid, 4-carboxylic acid, 3-sulfonic acid or 4- sulfonic acid
  • W is selected from 3-phenyl or 4-phenyl; in either case substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
  • X is selected from 3-carboxylic acid, 4-carboxylic acid, 3-sulfonic acid or 4- sulfonic acid;
  • W is N-phenyl substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
  • R* is phenyl substituted with either a carboxy or sulfonic acid
  • Z is NH
  • R 2 and R 3 are hydrogen;
  • L is either 3-biphenyl, 4-biphenyl or 1-N-phenylpyrazole substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F;
  • X OH; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
  • Preferred among the presently invented compounds are: 4-(naphth- 1 -yl)- 1 -(2,4,6-trihydroxybenzylidene)-3-thiosemicarbazide; l-(3,5-dichloro-2-hydroxybenzylidene)-4-(4-sulfophenyl)-3-thiosemicarbazide; l-[(2-hydroxynaphth-l-yl)methylidene]-4-(4-sulfophenyl)-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide; l-[l-(4-carboxy-2-hydroxyphenyl)ethylidene]-4-(naphth-l-yl)-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[(2-hydroxy
  • Compounds of Formula (I) are included in the pharmaceutical compositions of the invention and used in the methods of the invention.
  • protected hydroxy or “protected -OH” as used herein, is meant the alcoholic or carboxylic-OH groups which can be protected by conventional blocking groups in the art as described in "Protective Groups In Organic Synthesis” by Theodora W. Greene, Wiley-Interscience, 1981, New York. Compounds containing protected hydroxy groups may also be useful as intermediates in the preparation of the pharmaceutically active compounds of the invention.
  • aryl as used herein, unless otherwise defined, is meant a cyclic or polycyclic aromatic ring containing from 1 to 14 carbon atoms and optionally containing from one to five heteroatoms, provided that when the number of carbon atoms is 1 the aromatic ring contains at least four heteroatoms, when the number of carbon atoms is 2 the aromatic ring contains at least three heteroatoms, when the number of carbons is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom.
  • C ⁇ -C ⁇ 2aryl phenyl, naphthalene, 3,4-methylenedioxyphenyl, pyridine, biphenyl, quinoline, pyrimidine, quinazoline, thiophene, furan, pyrrole, pyrazole, imidazole and tetrazole.
  • ' ⁇ -Cgar l as used herein, unless otherwise defined, is meant a cyclic or polycyclic aromatic ring containing from 3 to 6 carbon atoms and optionally containing from one to 4 heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom.
  • substituted as used herein, unless otherwise defined, is meant that the subject chemical moiety has one or more substituents selected from the group consisting of: hydroxyalkyl, alkoxy, acyloxy, alkyl, aryl, amino, N-acylamino, hydroxy, -(CH2)gC(0)OR6, -S(0) n R 7 , nitro, cyano, halogen, trifluoromethyl and protected -OH, where g is 0-6, R° is hydrogen or alkyl, n is 0-3, and R 7 is hydrogen or alkyl.
  • alkoxy as used herein is meant -Oalkyl where alkyl is as described herein including -OCH 3 and -OC(CH 3 ) 2 CH3.
  • cycloalkyl as used herein unless otherwise defined, is meant a nonaromatic, unsaturated or saturated, cyclic or polycyclic C3-C12.
  • cycloalkyl and substituted cycloalkyl substituents as used herein include: cyclohexyl, 4-hydroxy-cyclohexyl, 2-ethylcyclohexyl, propyl 4- methoxycyclohexyl, 4-methoxycyclohexyl, 4-carboxycyclohexyl and cyclopentyl.
  • acyloxy as used herein is meant -OC(0)alkyl where alkyl is as described herein.
  • Examples of acyloxy substituents as used herein include: -0C(0)CH3, - OC(0)CH(CH 3 ) 2 and -OC(0)(CH 2 )3CH 3 .
  • N-acylamino as used herein is meant -N(H)C(0)alkyl, where alkyl is as described herein.
  • Examples of N-acylamino substituents as used herein include: - N(H)C(0)CH 3 , -N(H)C(0)CH(CH 3 ) 2 and -N(H)C(0)(CH 2 ) 3 CH 3 .
  • aryloxy as used herein is meant -OCg-C ⁇ 2aryl where Cg-Cj ⁇ aryl is phenyl, naphthyl, 3,4-methylenedioxyphenyl, pyridyl or biphenyl optionally substituted with one or more substituents selected from the group consisting of: alkyl, hydroxyalkyl, alkoxy, trifuloromethyl, acyloxy, amino, N-acylamino, hydroxy, -(CH2)gC(O)O ", - S(0) n R' , nitro, cyano, halogen and protected -OH, where g is 0-6, R° is hydrogen or alkyl, n is 0-3 and R' is hydrogen or alkyl.
  • substituents as used herein include: phenoxy, 4-fluorophenyloxy and biphenyloxy.
  • heteroatom as used herein is meant oxygen, nitrogen or sulfur.
  • halogen as used herein is meant a substituent selected from bromide, iodide, chloride and fluoride.
  • alkyl and derivatives thereof and in all carbon chains as used herein is meant a linear or branched, saturated or unsaturated hydrocarbon chain having C -C 2 carbon atoms.
  • treating and derivatives thereof as used herein, is meant prophylatic or therapeutic therapy.
  • esters can be employed, for example methyl, ethyl, pivaloyloxymethyl, and the like for -COOH, and acetate maleate and the like for -OH, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
  • novel compounds of Formula I are prepared analogously to the processes shown in Schemes I and II below wherein wherein Rl, R-**-, R*- ⁇ Z, Y, L and X are as defined in Formula I and provided that these substituents do not include any such substituents that render inoperative the processes of Schemes I and II. All of the starting materials are commercially available or are readily made from commercially available starting materials by those of skill in the art.
  • isocyanates or isothiocyanates are coupled with a hydrazine to produce semicarbazides or thiosemicarbazides.
  • the treatment of thrombocytopenia is accomplished by enhancing the production of platelets.
  • co-administering and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a TPO mimetic compound, as described herein, and a further active ingredient or ingredients, known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production.
  • the compounds are administered in a close time proximity to each other.
  • the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.
  • the pharmaceutically active compounds of the present invention are active as TPO mimetics they exhibit therapeutic utility in treating thrombocytopenia and other conditions with depressed platelet production.
  • Some of the preferred compounds of this invention were also active in an in vitro proliferation assay using the murine 32D-mpl cell line (Bartley, T. D. et al., Cell, 1994, 77, 1117-1124). 32D-mpl cells express Tpo-R and their survival is dependent on the presence of TPO.
  • compositions within the scope of this invention are useful as TPO mimetics in mammals, including humans, in need thereof.
  • Compound A (found in Example 15) showed activation of about 20% of control (control is the maximal response to TPO) at a concentration of 3 uM in the luciferase assay.
  • Some of the preferred compounds within the scope of the invention showed activation from about 5% to 60% control at a concentration of 0.1-30 uM in the luciferase assay.
  • the preferred compounds of the invention also promoted the proliferation of 32D- mpl cells at a concentration of 0.01 to 30 uM.
  • the most preferred compounds of this invention were found to stimulate the proliferation of BAF-3/TPO-responsive human cell lines with full TPO efficacy and with EC50 values below 100 nM as shown in Table 1.
  • the present invention therefore provides a method of treating thrombocytopenia and other conditions with depressed platelet production, which comprises administering a compound of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates and esters thereof in a quantity effective to enhance platelet production.
  • the compounds of Formula (I) also provide for a method of treating the above indicated disease states because of their demonstrated ability to act as TPO mimetics.
  • the drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral.
  • Solid or liquid pharmaceutical carriers are employed.
  • Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • Liquid carriers include syrup, peanut oil, olive oil, saline, and water.
  • the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit.
  • the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.
  • the pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.
  • Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 - 100 mg/kg of active compound, preferably 0.001 - 50 mg/kg.
  • the selected dose is administered preferably from 1-6 times daily, orally or parenterally.
  • Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion.
  • Oral dosage units for human administration preferably contain from 0.05 to 3500 mg of active compound. Oral administration, which uses lower dosages is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.
  • Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular TPO mimetic in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.
  • the method of this invention of inducing TPO mimetic activity in mammals, including humans comprises administering to a subject in need of such activity an effective TPO mimetic amount of a pharmaceutically active compound of the present invention.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use as a TPO mimetic.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in therapy.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in enhancing platelet production.
  • the invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in treating thrombocytopenia.
  • the invention also provides for a pharmaceutical composition for use as a TPO mimetic which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
  • the invention also provides for a pharmaceutical composition for use in the treatment of thrombocytopenia which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
  • the invention also provides for a pharmaceutical composition for use in enhancing platelet production which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
  • the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production, or compounds known to have utility when used in combination with a TPO mimetic.
  • further active ingredients such as other compounds known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production, or compounds known to have utility when used in combination with a TPO mimetic.
  • the compound was obtained from a commercial source (Maybridge Chemical Company Ltd.)
  • the compound was obtained from a commercial source (Maybridge Chemical Company Ltd.)
  • Example 3 l-(3,5-dichloro-2-hvdroxybenzvIidene)-4-(4-ethoxycarbonylphenyl)-3-thiosemicarbazide
  • the compound was obtained from a commercial source (Maybridge Chemical Company Ltd.)
  • Example 15 4-(4-carboxyphenyl)-l-[2-methoxy-3-(4-methylphenyl)benzylidene1-3-thiosemicarbazide.
  • a solution of 4-(4-carboxyphenyl)-3-thiosemicarbazide (11 mg, 0.05 mmol) and 2- methoxy-3-(4-methylphenyl)benzaldehyde (14 mg, 0.06 mmol) in dimethylformamide (1 mL) was shaken with 4A molecular sieves for 40 h.
  • PS-TsNHNH2 resin 17. mg, 0.05 mmol
  • Example 16 - Capsule Composition An oral dosage form for administering a presently invented agonist of the TPO receptor is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table II, below.
  • Example 17 Magnesium Stearate 4 mg
  • Example 17 An injectable form for administering a presently invented agonist of the TPO receptor is produced by stirring 1.5% by weight of 4-(3-carboxyphenyl)-l-[3-(3,4- dimethylphenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide (Compound A), in 10% by volume propylene glycol in water.
  • Compound A 4-(3-carboxyphenyl)-l-[3-(3,4- dimethylphenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide
  • Example 18 Tablet Composition
  • sucrose, calcium sulfate dihydrate and a presently invented agonist of the TPO receptor as shown in Table III below, are mixed and granulated in the proportions shown with a 10% gelatin solution.
  • the wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
  • Particularly preferred among the compounds of the present invention are the following.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invented are non-peptide TPO mimetics. also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted thiosemicarbazone derivative.

Description

THROMBOPOIETIN MIMETICS
FIELD OF THE INVENTION This invention relates to thrombopoietin (TPO ) mimetics and their use as promoters of thrombopoiesis and megakaryocytopoiesis.
BACKGROUND OF THE INVENTION
Thrombopoietin (TPO) is a 332-amino acid glycosylated polypeptide which plays a key role in the regulation of megakaryocytopoiesis, the process in which platelets are produced from bone marrow megakaryocytes. See Kuter et al.JProc. Natl. Acad. Sci. USA 91: 11104-11108 (1994); Barley et al., Cell 77:1117-1124 (1994): Kaushanskv et al„ Nature 369:568-571 (1994); Wendling et al., Nature 369: 571-574 (1994); and Sauvage et al., Nature 369: 533-538 (1994). TPO is produced in the liver but exerts its main function in the bone marrow, where it stimulates the differentiation of stem cells into megakaryocyte progenitors as well as megakaryocyte proliferation, polyploidization and, ultimately, their fragmentation into circulating platelet bodies. TPO is also the primary regulator of situations involving thrombocytopenia and has been shown in a number of studies to increase platelet counts, increase platelet size, and increase isotope incorporation into platelets of recipient animals. See, e.g., Metcalf Nature 369:519-520 (1994). Specifically, TPO is thought to affect megakaryocytopoiesis in several ways: (1) it produces increases in megakaryocyte size and number; (2) it produces an increase in DNA content, in the form of polyploidy, in megakaryocytes; (3) it increases megakaryocyte endomitosis; (4) it produces increased maturation of megakaryocytes; and (5) it produces an increase in the percentage of precursor cells, in the form of small acetylcholinesterase- positive cells, in the bone marrow.
Platelets are necessary for blood clotting and when their numbers are very low a patient is at risk of death from catastrophic hemorrhage. Thus, TPO has potential useful application in both the diagnosis and the treatment of various hematological disorders, for example, diseases primarily due to platelet defects. Likewise, TPO has potential application in the treatment of thrombocytopenic conditions, especially those derived from chemotherapy, radiation therapy, or bone marrow transplantation as treatment for cancer or lymphoma. Indeed, ongoing clinical trials in cancer patients have shown that recombinant human TPO is effective in decreasing the platelet nadir and enhancing platelet recovery when given with high-dose carboplatin chemotherapy. See Basser Blood, 1997, 89: 3118. Similar results have also been obtained in clinical studies with pegylated megakaryocyte differentiation factor (peg-MGDF, a pegylated truncated N-terminal fragment of human TPO). See e.g., Fanucchi (1997) N Engl J Med, 336: 404.
Because the slow recovery of platelet levels in patients suffering from thrombocytopenia is a serious problem, it would be desirable to provide compounds which allow for the treatment of thrombocytopenia by acting as a TPO mimetic. A few years ago, the development of TPO peptide mimetics was reported (WO 96/4018, WO 96/40750, WO 98/25965). These peptides were designed to bind and activate the TPO-R but have no sequence homology to the natural TPO. In recent years, a number of small-molecule agents with TPO mimetic activity been reported. These include l,4-benzodiazepin-2-ones (JP11001477), metal complexes derived from Schiff base ligands (WO 99/11262), cyclic polyamine derivatives (WO 00/28987), thiazol-2-yl-benzamides (WO 01/07423, WO 01/53267), azo-aryl derivatives (WO 00/35446, WO 1/17349), 2-aryl-naphthimidazoles (WO 01/39773, WO 01/53267) and semicarbazone derivatives (WO 01/34585). In cell-based systems, all these molecules can activate signal transduction pathways that are dependent on the presence of the TPO receptor on the cell membrane, suggesting some type of direct interaction with the TPO receptor itself. As disclosed herein it has unexpectedly been discovered that certain substituted thiosemicarbazone derivatives are very effective and potent agonists of the TPO receptor. Some of the most preferred compounds of this class were found to stimulate the proliferation and differentiation of TPO-responsive human cell lines and human bone marrow cultures with full TPO efficacy at concentrations below 100 nM.
SUMMARY OF THE INVENTION
This invention relates to compounds of Formula (I):
Figure imgf000003_0001
wherein: R! is aryl, optionally substituted with 1 or more substituents selected from Ci- lOalkyl, aryl, heteroaryl, halogen, -C(0)OR7, -CONR7R8, -S(0)nR6, - S(0)2NR'R°, sulfonyloxy, nitro, optionally substituted amino, hydroxy, alkoxy;
R is selected from hydrogen, Ci _ι 2alkyl, aryl, substituted aryl, and alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryl, substituted aryl, amino, N-acylamino, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, -C(0)OR7, -S(0)2NR7R8, -S(0)nR6, aryloxy, nitro, cyano, halogen, and protected -OH, where
R° is selected from hydrogen, alkyl, cycloalkyl, CJ-CJ 2aryl> substituted alkyl, substituted cycloalkyl and substituted Cj-C^aryl, and R' and R° are independently selected from hydrogen, cycloalkyl, aryl, substituted cycloalkyl, substituted aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -C(0)OR", -S(0)nR°, - C(0)NR6R6, -S(0)2NR6R6, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, Cι-Ci2aryl> substituted C j-Cj 2aryl and protected -OH where R" is as described above; n is 0-3;
Z is selected from S or NR where R2 is as defined above;
R3 is selected from hydrogen, Cj -C jgalkyl, phenyl, substituted phenyl, carboxyl or C i -C j galkoxy carbony 1 ;
L is naphthyl or a group of formula (L):
Figure imgf000004_0001
(L)
where A, B, D and E independently represent CR! 1 or N; where R! 1 is selected from hydrogen, halogen, -CF , -CN, -SO3H, -S03Na, -S02R14, -N02, phenyl, substituted phenyl, Cj-Cjoalkyl, C^-C jgalko y, Cι-Cιoacyl°χy> arylalkoxy, - COR14, -NR12R13, hydroxy or cycloalkyl; where Rl4 is selected from hydroxy, Ci -Ciøalkyl, phenyl, amino, mono- or dialkylamino; Rl2 and R13 are independently selected from hydrogen, C^.^oalkyl, C^-C^ ry!, substituted Cj-Cj 2 ryl, C^øacyl or cycloalkyl; or either A=B or D=E alternatively represent O, S or NR12; where R12 is as defined above;
Y is selected from -S, -O and -NRl^; where R^ is selected from hydrogen, Cι- Cjoalkyl, substituted Cj-Cjoalkyl, Cj-Cgalkylphenyl, substituted Cj- Cgalkylphenyl,
Figure imgf000005_0001
is Cj- C^oalkyl, substituted C;[-Cιoalkyl, CJ-CT 2 ryl or substituted Cj-C^aryl; and
X is selected from -SR16, -OR16 or -NHR17; where R16 is hydrogen, C^C^a-kyl or substituted CT -Cjøalkyl; R!7 is hydrogen, Cj-Ciøalkyl, substituted Cj-Cioalkyl, C^-Cgalkylphenyl, Ci-
Cjoacyl or substituted Cι-Cjoacyl; and
pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
This invention relates to a method of treating thrombocytopenia, which comprises administering to a subject in need thereof an effective amount of a TPO mimetic compound of Formula (I).
The present invention also relates to the discovery that the compounds of Formula (I) are active as agonists of the TPO receptor.
In a further aspect of the invention there is provided novel processes and novel intermediates useful in preparing the presently invented TPO mimetic compounds.
Included in the present invention are pharmaceutical compositions comprising a pharmaceutical carrier and compounds useful in the methods of the invention.
Also included in the present invention are methods of co-administering the presently invented TPO mimetic compounds with further active ingredients.
DETAILED DESCRIPTION OF THE INVENTION This invention relates to compounds of Formula (I) as described above.
Preferred among the presently invented Formula I compounds are those in which R S Cj-C^aryl, particularly phenyl, substituted with a carboxy or sulfonic acid substituent.
Preferred among the presently invented Formula I compounds are those in which R1 and R**-* are independently selected from hydrogen, C\ .iQalkyl, Cj_i2aryl and substituted C\_\ 2aryl.
Preferred among the presently invented Formula I compounds are those in which:
Z is S or -NR2 where R2 is as defined above;
L is C3-Cgaryl optionally substituted with form 1 to 3 substituents selected from the group consisting of: hydroxy, nitro, -C(0)OH, alkyl, substituted alkyl, C _
12aryl, substituted C\ _\ 2aryl, Br, CI, CF3 and F; Y is S; and
X is -OH or methoxy; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
Also preferred among the presently invented Formula I compounds are those in which: Rl is phenyl, substituted with either carboxylic acid or sulfonic acid; Z, R****, R , L, X and Y are as described in claim 1 ; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
Also preferred among the presently invented Formula I compounds are those in which: Z is NH;
R2 and R3 are hydrogen; Y = S;
R\ L, X are as described in claim 1; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
Also preferred among the presently invented Formula I compounds are those in which: L is selected from 3-biphenyl , 4-biphenyl or 1-N-phenylpyrazole substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F;
X = OH;
Z, R1, R2, R3 and Y are as described in claim 1; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
Also preferred among the presently invented Formula I compounds are compounds of formula (II) wherein:
Figure imgf000007_0001
X is selected from 3-carboxylic acid, 4-carboxylic acid, 3-sulfonic acid or 4- sulfonic acid; W is selected from 3-phenyl or 4-phenyl; in either case substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
Also preferred among the presently invented Formula I compounds are compounds of formula (III) wherein:
Figure imgf000008_0001
X is selected from 3-carboxylic acid, 4-carboxylic acid, 3-sulfonic acid or 4- sulfonic acid; W is N-phenyl substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
Most preferred among the presently invented Formula I compounds are those in which: R* is phenyl substituted with either a carboxy or sulfonic acid; Z is NH;
R2 and R3 are hydrogen; L is either 3-biphenyl, 4-biphenyl or 1-N-phenylpyrazole substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F; X = OH; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
Preferred among the presently invented compounds are: 4-(naphth- 1 -yl)- 1 -(2,4,6-trihydroxybenzylidene)-3-thiosemicarbazide; l-(3,5-dichloro-2-hydroxybenzylidene)-4-(4-sulfophenyl)-3-thiosemicarbazide; l-[(2-hydroxynaphth-l-yl)methylidene]-4-(4-sulfophenyl)-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide; l-[l-(4-carboxy-2-hydroxyphenyl)ethylidene]-4-(naphth-l-yl)-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[(2-hydroxynaphth-l-yl)methylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[(2-hydroxynaphth-l-yl)methylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide; l-(4-carboxy-2-hydroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide; -(4-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide; l-(4-benzyloxy-2-hydroxybenzylidene)-4-(4-carboxyphenyl)-3-thiosemicarbazide; l-(4-benzyloxy-2-hydroxybenzylidene)-4-(3-carboxyphenyl)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(5-chloro-2-hydroxybenzylidene)-3-thiosemicarbazide; -(4-carboxyphenyl)- 1 - [( 1 -hy droxynaphth-2-yl)methylidene] -3- thiosemicarbazide ;
4-(3-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(2-hydroxy-5-methylbenzylidene)-3-thiosemicarbazide; l-(2,4-dihydroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide; l-(2-hydroxy-3-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide;
4-(3-chloro-2-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide; l-(2-hydroxy-4-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide;
4-(3-chloro-4-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide; l-(2-hydroxy-4-carboxybenzylidene)-4-(4-methylphenyl)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-methoxy-3-(4-methylphenyl)benzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-methoxybenzylidene]-3- thiosemicarbazide ; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide ; 4-(4-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]fiιran-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide ; 4-(3-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide ; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(3-chlorophenyI)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide ; 4-(4-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide ; 4-(3-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)- 1 -[ { 1 -(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide ; 4-(4-carboxyphenyl)-l-[{ l-(3-chlorophenyI)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; and 4-(3-carboxyρhenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide.
Preferred compounds for use in the presently invented compositions and methods are:
4-(4-chloro-2-methylphenyl)-l-(3,5-dinitro-2-hydroxybenzylidene)-3-thiosemicarbazide; l-(3,5-dinitro-2-hydroxybenzylidene)-4-(2-methylphenyl)-3-thiosemicarbazide; l-(3,5-dichloro-2-hydroxybenzylidene)-4-(4-ethoxycarbonylphenyl)-3-thiosemicarbazide; -(naphth-l-yl)-l-(2,4,6-trihydroxybenzylidene)-3-thiosemicarbazide; l-(3,5-dichloro-2-hydroxybenzylidene)-4-(4-sulfophenyl)-3-thiosemicarbazide; l-[(2-hydroxynaphth-l-yl)methylidene]-4-(4-sulfophenyl)-3-thiosemicarbazide; -(4-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide; l-[l-(4-carboxy-2-hydroxyphenyl)ethylidene]-4-(naphth-l-yl)-3-thiosemicarbazide; -(4-carboxyphenyl)- 1 - [(2-hydroxynaphth- l-yl)methylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[(2-hydroxynaphth-l-yl)methylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide; l-(4-carboxy-2-hydroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide; l-(4-benzyloxy-2-hydroxybenzylidene)-4-(4-carboxyphenyl)-3-thiosemicarbazide; l-(4-benzyloxy-2-hydroxybenzylidene)-4-(3-carboxyphenyl)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(5-chloro-2-hydroxybenzylidene)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(2-hydroxy-5-methylbenzylidene)-3-thiosemicarbazide; l-(2,4-dihydroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide; l-(2-hydroxy-3-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide;
4-(3-chloro-2-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide; l-(2-hydroxy-4-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide;
4-(3-chloro-4-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide; l-(2-hydroxy-4-carboxybenzylidene)-4-(4-methylphenyl)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-methoxy-3-(4-methylphenyl)benzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-methoxybenzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide; -(4-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide; -(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide; -(4-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide; -(3-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide; -(4-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; -(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; -(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide; -(3-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide; -(4-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide; -(3-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide; -(4-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; -(3-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; -(4-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide; -(3-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide; -(4-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide; -(3-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide; -(4-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; -(3-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; -(4-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide; -(3-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide; -(4-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide; -(3-carboxyphenyl)-l-[{l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide; -(4-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; and 4-(3-carboxyphenyl)-l-[{l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]- 3-thiosemicarbazide.
Particularly preferred among the presently invented compounds are: 4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide;
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(4-carboxyphenyl)- 1- [ { 5-hydroxy-3-methyl- 1 -(4-methylphenyl)pyrazol-4-yl } methylene]- 3-thiosemicarbazide;
4-(3-carboxyphenyl)- 1 - [ { 5-hydroxy-3-methyl- l-(4-methylphenyl)pyrazol-4-yl Jmethylene]- 3-thiosemicarbazide; and
4-(4-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]- 3-thiosemicarbazide.
Compounds of Formula (I) are included in the pharmaceutical compositions of the invention and used in the methods of the invention.
By the term "protected hydroxy" or "protected -OH" as used herein, is meant the alcoholic or carboxylic-OH groups which can be protected by conventional blocking groups in the art as described in "Protective Groups In Organic Synthesis" by Theodora W. Greene, Wiley-Interscience, 1981, New York. Compounds containing protected hydroxy groups may also be useful as intermediates in the preparation of the pharmaceutically active compounds of the invention.
By the term "aryl" as used herein, unless otherwise defined, is meant a cyclic or polycyclic aromatic ring containing from 1 to 14 carbon atoms and optionally containing from one to five heteroatoms, provided that when the number of carbon atoms is 1 the aromatic ring contains at least four heteroatoms, when the number of carbon atoms is 2 the aromatic ring contains at least three heteroatoms, when the number of carbons is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom.
By the term "Cχ-Cχ2aryl" as used herein, unless otherwise defined, is meant phenyl, naphthalene, 3,4-methylenedioxyphenyl, pyridine, biphenyl, quinoline, pyrimidine, quinazoline, thiophene, furan, pyrrole, pyrazole, imidazole and tetrazole.
By the term '^-Cgar l" as used herein, unless otherwise defined, is meant a cyclic or polycyclic aromatic ring containing from 3 to 6 carbon atoms and optionally containing from one to 4 heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom.
By the term "substituted" as used herein, unless otherwise defined, is meant that the subject chemical moiety has one or more substituents selected from the group consisting of: hydroxyalkyl, alkoxy, acyloxy, alkyl, aryl, amino, N-acylamino, hydroxy, -(CH2)gC(0)OR6, -S(0)nR7, nitro, cyano, halogen, trifluoromethyl and protected -OH, where g is 0-6, R° is hydrogen or alkyl, n is 0-3, and R7 is hydrogen or alkyl.
By the term "alkoxy" as used herein is meant -Oalkyl where alkyl is as described herein including -OCH3 and -OC(CH3)2CH3.
The term "cycloalkyl" as used herein unless otherwise defined, is meant a nonaromatic, unsaturated or saturated, cyclic or polycyclic C3-C12.
Examples of cycloalkyl and substituted cycloalkyl substituents as used herein include: cyclohexyl, 4-hydroxy-cyclohexyl, 2-ethylcyclohexyl, propyl 4- methoxycyclohexyl, 4-methoxycyclohexyl, 4-carboxycyclohexyl and cyclopentyl.
By the term "acyloxy" as used herein is meant -OC(0)alkyl where alkyl is as described herein. Examples of acyloxy substituents as used herein include: -0C(0)CH3, - OC(0)CH(CH3)2 and -OC(0)(CH2)3CH3.
By the term "N-acylamino" as used herein is meant -N(H)C(0)alkyl, where alkyl is as described herein. Examples of N-acylamino substituents as used herein include: - N(H)C(0)CH3, -N(H)C(0)CH(CH3)2 and -N(H)C(0)(CH2)3CH3.
By the term "aryloxy" as used herein is meant -OCg-Cχ2aryl where Cg-Cj^aryl is phenyl, naphthyl, 3,4-methylenedioxyphenyl, pyridyl or biphenyl optionally substituted with one or more substituents selected from the group consisting of: alkyl, hydroxyalkyl, alkoxy, trifuloromethyl, acyloxy, amino, N-acylamino, hydroxy, -(CH2)gC(O)O ", - S(0)nR' , nitro, cyano, halogen and protected -OH, where g is 0-6, R° is hydrogen or alkyl, n is 0-3 and R' is hydrogen or alkyl. Examples of aryloxy substituents as used herein include: phenoxy, 4-fluorophenyloxy and biphenyloxy.
By the term "heteroatom" as used herein is meant oxygen, nitrogen or sulfur. By the term "halogen" as used herein is meant a substituent selected from bromide, iodide, chloride and fluoride.
By the term "alkyl" and derivatives thereof and in all carbon chains as used herein is meant a linear or branched, saturated or unsaturated hydrocarbon chain having C -C 2 carbon atoms. Examples of alkyl substituents as used herein include: -CH3, -CH2-CH3, -CH2-CH2-CH3, -CH(CH3)2, -C(CH3)3, -(CH2)3-CH3, -CH2-CH(CH3)2 and -CH(CH3)- CH2-CH3, -CH=CH2.
By the term "treating" and derivatives thereof as used herein, is meant prophylatic or therapeutic therapy.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as though fully set forth.
Compounds of Formula (I) are included in the pharmaceutical compositions of the invention and used in the methods of the invention. Where a -COOH or -OH group is present, pharmaceutically acceptable esters can be employed, for example methyl, ethyl, pivaloyloxymethyl, and the like for -COOH, and acetate maleate and the like for -OH, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
The novel compounds of Formula I are prepared analogously to the processes shown in Schemes I and II below wherein wherein Rl, R-**-, R*-\ Z, Y, L and X are as defined in Formula I and provided that these substituents do not include any such substituents that render inoperative the processes of Schemes I and II. All of the starting materials are commercially available or are readily made from commercially available starting materials by those of skill in the art.
Scheme I
Figure imgf000015_0001
(3)
Compounds I, are condensed with carbonyl compounds 2, available commercially or prepared by literature methods, in a suitable solvent with or without the addition of an acid catalyst such as HC1 to furnish the final compound 3.
Scheme II
Figure imgf000016_0001
a) THF
Commercially available isocyanates or isothiocyanates are coupled with a hydrazine to produce semicarbazides or thiosemicarbazides.
The treatment of thrombocytopenia, as described herein, is accomplished by enhancing the production of platelets.
By the term "co-administering" and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a TPO mimetic compound, as described herein, and a further active ingredient or ingredients, known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production. Preferably, if the administration is not simultaneous, the compounds are administered in a close time proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.
Because the pharmaceutically active compounds of the present invention are active as TPO mimetics they exhibit therapeutic utility in treating thrombocytopenia and other conditions with depressed platelet production.
In determining potency as TPO mimetics, the following assays were employed: Luciferase Assay
Compounds of the present invention were tested for potency as mimetics of the TPO receptor in a Luciferase assay such as described in Lamb, et al., Nucleic Acids Research 23: 3283-3289 (1995) and Seidel, et al., Proc. Natl. Acad. Sci.. USA 92: 3041- 3045 (1995) by substituting a TPO-responsive BaF3 cell line (Vigon et al. Proc. Natl. Acad. Sci. USA 1992, 89, 5640-5644) for the HepG2 cells utilized therein. The murine BaF3 cells express TPO receptors and closely match the pattern of STAT (signal transducers and activators of transcription) activation observed in primary murine and human bone marrow cells in response to TPO.
Some of the preferred compounds of this invention were also active in an in vitro proliferation assay using the murine 32D-mpl cell line (Bartley, T. D. et al., Cell, 1994, 77, 1117-1124). 32D-mpl cells express Tpo-R and their survival is dependent on the presence of TPO.
The pharmaceutically active compounds within the scope of this invention are useful as TPO mimetics in mammals, including humans, in need thereof.
Within the scope of the invention Compound A (found in Example 15) showed activation of about 20% of control (control is the maximal response to TPO) at a concentration of 3 uM in the luciferase assay.
Some of the preferred compounds within the scope of the invention showed activation from about 5% to 60% control at a concentration of 0.1-30 uM in the luciferase assay. The preferred compounds of the invention also promoted the proliferation of 32D- mpl cells at a concentration of 0.01 to 30 uM.
The most preferred compounds of this invention were found to stimulate the proliferation of BAF-3/TPO-responsive human cell lines with full TPO efficacy and with EC50 values below 100 nM as shown in Table 1.
Table 1
Example # ECsf/uM Efficacy/ΨoTPOmπx
15.8 0.03 90
15.9 0.02 100
15.10 0.05 100
15.12 0.06 85
15.29 0.03 100
15.30 0.03 100
15.31 0.03 100
The present invention therefore provides a method of treating thrombocytopenia and other conditions with depressed platelet production, which comprises administering a compound of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates and esters thereof in a quantity effective to enhance platelet production. The compounds of Formula (I) also provide for a method of treating the above indicated disease states because of their demonstrated ability to act as TPO mimetics. The drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral.
The pharmaceutically active compounds of the present invention are incorporated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers are employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.
The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.
Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 - 100 mg/kg of active compound, preferably 0.001 - 50 mg/kg. When treating a human patient in need of a TPO mimetic, the selected dose is administered preferably from 1-6 times daily, orally or parenterally. Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion. Oral dosage units for human administration preferably contain from 0.05 to 3500 mg of active compound. Oral administration, which uses lower dosages is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular TPO mimetic in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.
The method of this invention of inducing TPO mimetic activity in mammals, including humans, comprises administering to a subject in need of such activity an effective TPO mimetic amount of a pharmaceutically active compound of the present invention.
The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use as a TPO mimetic.
The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in therapy.
The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in enhancing platelet production. The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in treating thrombocytopenia.
The invention also provides for a pharmaceutical composition for use as a TPO mimetic which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
The invention also provides for a pharmaceutical composition for use in the treatment of thrombocytopenia which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
The invention also provides for a pharmaceutical composition for use in enhancing platelet production which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
In addition, the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production, or compounds known to have utility when used in combination with a TPO mimetic.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.
Experimental Details
Example 1 4-(4-chloro-2-methylphenyl)-l-("3,5-dinitro-2-hvdroxybenzylidene)-3-thiosemicarbazide
The compound was obtained from a commercial source (Maybridge Chemical Company Ltd.)
Example 2 l-(3.5-dinitro-2-hvdroxybenzylidene)-4-(2-methylphenyl)-3-thiosemicarbazide
The compound was obtained from a commercial source (Maybridge Chemical Company Ltd.)
Example 3 l-(3,5-dichloro-2-hvdroxybenzvIidene)-4-(4-ethoxycarbonylphenyl)-3-thiosemicarbazide The compound was obtained from a commercial source (Maybridge Chemical Company Ltd.)
Example 4 4-(naphth-l-yl)-l-(2A6-trihvdroxybenzylidene)-3-thiosemicarbazide
A solution of 4-(naphth-l-yl)thiosemicarbazide (572 mg, 2.63 mmol) and 2,4,6- trihydroxybenzaldehyde (405 mg, 2.63 mmol) in acetic acid (5 mL) was heated under reflux for 20 min, then cooled. The precipitate was filtered, washed (acetic acid) and dried to give the title compound (445 mg, 54%) as a solid. MS (ES+) m/e 354 [M+H]+.
Example 5 l-(3,5-dichloro-2-hydroxybenzylidene)-4-(4-sulfophenyl)-3-thiosemicarbazide a) 4-(4-sulfophenyl)-3-thiosemicarbazide, sodium salt
A solution of hydrazine in tetrahydrofuran (1M, 9.2 mL, 9.2 mmol) was added slowly to a stirred mixture of sodium 4-isothiocyanatobenzenesulfonate (2.36 g, 9.2 mmol) and tetrahydrofuran (60 mL). After 4 h, ether was added, then the solid filtered, washed (ether) and dried to give the title compound (2.47 g, 100%) as a solid. MS (ES-) m/e 246 [M-H]-. b) l-(3,5-dichloro-2-hydroxybenzylidene)-4-(4-sulfophenyl)-3-thiosemicarbazide
A mixture of 4-(4-sulfophenyl)-3-thiosemicarbazide, sodium salt (740 mg, 2.75 mmol), 3,5-dichloro-2-hydroxybenzaldehyde (577 mg, 3.02 mmol), concentrated aqueous hydrochloric acid (0.3 mL) and ethanol (10 mL) was heated under reflux for 20 min. then cooled. The solid was filtered, washed (water) and dried to give the title compound (277 mg, 24%) as a solid. MS (ES-) m/e 418, 420 [M-H]-.
Example 6 l-r(2-hydroxynaphth-l-yl)methylidenel-4-(4-sulfophenyl)-3-thiosemicarbazide
The procedure described in example 4 was followed here, using 4-(4-sulfophenyl)- 3-thiosemicarbazide, sodium salt in place of 4-(naphth-l-yl)thiosemicarbazide and 2- hydroxy-1-naphthaldehyde in place of 2,4,6-trihydroxybenzaldehyde to give the title compound (23%) as a solid. MS (ES-) m e 400 [M-H]-.
Example 7 4-(4-carboxyphenyl)-l-(3.5-dichloro-2-hvdroxybenzylidene)-3-thiosemicarbazide
Concentrated aqueous hydrochloric acid (1 mL) was added to a stirred solution of 4-(4-carboxyphenyl)-3-thiosemicarbazide (213 mg, 1.00 mmol) and 3,5-dichloro-2- hydroxybenzaldehyde (198 mg, 1.04 mmol) in dimethylformamide (20 mL). The mixture was stirred for 18 h, water was added and the precipitate filtered, washed (water) and dried to give the title compound (212 mg, 55%) as a solid. MS (ES-) m/e 382, 384 [M-H]-.
Example 8 l-ri-(4-carboxy-2-hydroxyphenyl ethylidenel-4-(naphth-l-yl)-3-thiosemicarbazide
The procedure described in example 7 was followed here, using 4-(naphth-l-yl)-3- thiosemicarbazide in place of 4-(4-carboxyphenyl)-3-thiosemicarbazide and 4-carboxy-2- hydroxyacetophenone in place of 3,5-dichloro-2-hydroxybenzaldehyde to give the title compound (26%) as a solid. MS (ES-) m/e 378 [M-H]-.
Example 9 4-(4-carboxyphenyl)-l-r('2-hvdroxynaphth-l-yl)methylidenel-3-thiosemicarbazide
The procedure described in example 7 was followed here, using 2-hydroxy-l- naphthaldehyde in place of 3,5-dichloro-2-hydroxybenzaldehyde to give the title compound (46%) as a solid. MS (ES-) m/e 364 [M-H]-.
Example 10 4-(3-carboxyphenyl)-l-r(2-hvdroxynaphth-l-yl)methylidene1-3-thiosemicarbazide
The procedure described in example 7 was followed here, using 4-(3- carboxyphenyl)-3-thiosemicarbazide in place of 4-(4-carboxyphenyl)-3-thiosemicarbazide and 2-hydroxy-l -naphthaldehyde in place of 3,5-dichloro-2-hydroxybenzaldehyde to give the title compound (49%) as a solid. MS (ES-) m/e 364 [M-H]-.
Example 11 4-(3-carboxyphenyl)-l-,3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide
The procedure described in example 7 was followed here, using 4-(3- carboxyphenyl)-3-thiosemicarbazide in place of 4-(4-carboxyphenyl)-3-thiosemicarbazide to give the title compound (26%) as a solid. MS (ES-) m/e 382, 384 [M-H]-.
Example 12 l-(4-carboxy-2-hvdroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide
A solution of 4-(naphth-l-yl)-3-thiosemicarbazide (38 mg, 0.175 mmol) and 4- carboxy-2-hydroxybenzaldehyde (35 mg, 0.211 mmol) in dimethylformamide (2 mL) was shaken with 4A molecular sieves for 2.5 h. PS-TsNHNH2 resin (50 mg, 0.147 mmol) was added, shaking continued for 1 h, then the resin filtered off. Water was added to the filtrate and the precipitated solid was filtered, washed (water, ether) and dried to give the title compound (52 mg, 81%) as a solid. MS (ES+) m/e 366 [M+H]+. Example 13 4-(4-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide
A solution of 4-(4-carboxyphenyl)-3-thiosemicarbazide (25 mg, 0.12 mmol) and 3,5-dibromo-2-hydroxybenzaldehyde (40 mg, 0.144 mmol) in dimethylsulfoxide (1 mL) was shaken with 4A molecular sieves for 18 h. Dimethylformamide (1 mL) was added, followed by PS-TsNHNH2 resin (80 mg, 0.230 mmol), shaking continued for 24 h, then the resin filtered off. The solution was chromatographed by reverse phase HPLC (CombiPrep ODS-A, 10-90% acetonitrile/water + 0.1% trifluoroacetic acid) to give the title compound (24 mg, 42%) as a solid. MS (ES-) m/e 470, 472, 474 [M-H]-.
The following compounds were prepared by the method described in example 13:
4-(3-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide. Yield 26%. MS (ES-) m/e 470, 472, 474 [M-H]-. l-(4-benzyloxy-2-hydroxybenzylidene)-4-(4-carboxyphenyl)-3-thiosemicarbazide. Yield 35%. MS (ES-) m e 420 [M-H]-. l-(4-benzyloxy-2-hydroxybenzylidene)-4-(3-carboxyphenyl)-3-thiosemicarbazide. Yield 16%. MS (ES-) m/e 420 [M-H]-.
4-(3-carboxyphenyl)-l-(5-chloro-2-hydroxybenzylidene)-3-thiosemicarbazide. Yield 33%. MS (ES-) m/e 348, 350 [M-H]-.
4-(4-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide. Yield 50%. MS (ES-) m/e 364 [M-H]-.
4-(3-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide. Yield 41%. MS (ES-) m/e 364 [M-H]-.
4-(4-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide. Yield 37%. MS (ES-) m/e 426 [M-H]-.
4-(3-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide. Yield 22%. MS (ES-) m/e 426 [M-H]-.
4-(4-carboxyphenyl)- l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide. Yield 18%. MS (ES-) m/e 328 [M-H]-.
4-(3-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide. Yield 15%. MS (ES-) m/e 328 [M-H]-.
4-(3-carboxyphenyl)-l-(2-hydroxy-5-methylbenzylidene)-3-thiosemicarbazide. Yield 40%. MS (ES-) m/e 328 [M-H]-.
Example 14 l-(2.4-dihvdroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide.
A solution of 4-(naphth-l-yl)-3-thiosemicarbazide (26 mg, 0.12 mmol) and 2,4- dihydroxybenzaldehyde (20 mg, 0.144 mmol) in dimethylformamide (1 mL) was shaken with 4A molecular sieves for 60 h. PS-TsNHNH2 resin (29 mg, 0.085 mmol) was added and shaking continued for 40 h, then the resin was filtered off. The solvent was removed under vacuum and the residue dissolved in ethanol. The solvent was again removed and the process repeated to give the title compound (7 mg, 18%) as a solid. MS (ES-) m/e 336 [M- H]-. The following compounds were prepared by the method described in example 14:
l-(2-hydroxy-3-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide. Yield 14%. MS (ES-) m/e 390 [M-H]-.
4-(3-chloro-2-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide. Yield 21%. MS (ES-) m e 362, 364 [M-H]-. l-(2-hydroxy-4-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide. Yield 11%. MS (ES-) m/e 390 [M-H]-.
4-(3-chloro-4-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide. Yield 14%. MS (ES-) m/e 362, 364 [M-H]-.
1 -(2-hydroxy-4-carboxybenzylidene)-4-(4-methylphenyl)-3-thiosemicarbazide. Yield 15%. MS (ES-) m e 328 [M-H]-.
Example 15 4-(4-carboxyphenyl)-l-[2-methoxy-3-(4-methylphenyl)benzylidene1-3-thiosemicarbazide. A solution of 4-(4-carboxyphenyl)-3-thiosemicarbazide (11 mg, 0.05 mmol) and 2- methoxy-3-(4-methylphenyl)benzaldehyde (14 mg, 0.06 mmol) in dimethylformamide (1 mL) was shaken with 4A molecular sieves for 40 h. PS-TsNHNH2 resin (17 mg, 0.05 mmol) was added and shaking continued for 24 h, then the resin was filtered off. The solvent was removed under vacuum and the residue chromatographed by reverse phase HPLC (CombiPrep ODS-A, 10-90% acetonitrile/water + 0.1% trifluoroacetic acid) to give the title compound (3 mg, 14%) as a solid. MS (ES-) m/e 418 [M-H]-.
The following compounds were prepared by the method described in example 15:
4-(3-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide. Yield 36%. MS (ES-) m/e 422 [M-H]-.
4-(4-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide. Yield 32%. MS (ES-) m/e 438, 440 [M-H]-. 4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide. Yield 50%. MS (ES-) m/e 438, 440 [M-H]-.
4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-methoxybenzylidene]-3- thiosemicarbazide. Yield 36%. MS (ES-) m/e 494 [M-H]-.
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide. Yield 35%. MS (ES-) m/e 404 [M-H]-.
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide. Yield 24%. MS (ES-) m/e 404 [M-H]-.
4-(4-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide. Yield 25%. MS (ES-) m/e 418 [M-H]-. 4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide. Yield 33%. MS (ES-) m/e 418 [M-H]-. (Ex.# 15.8 - Compound A) 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide. Yield 27%. MS (ES-) m/e 458 [M-H]-. (Ex.# 15.9 - Compound B) 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide. Yield 41%. MS (ES-) m/e 458 [M-H]-. (Ex.# 15.10 - Compound C) 4-(4-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide. Yield 33%. MS (ES-) m/e 408 [M-H]-.
4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide. Yield 26%. MS (ES-) m/e 424 [M-H]-. (Ex.# 15.12 - Compound D) 4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide. Yield 42%. MS (ES-) m/e 480 [M-H]-. 4-(3-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide. Yield 50%. MS (ES-) m e 480 [M-H]-.
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide. Yield 21%. MS (ES-) m/e 440 [M-H]-.
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide. Yield 33%. MS (ES-) m e 440 [M-H]-.
4-(4-carboxyphenyl)- 1 - [3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide. Yield 25%. MS (ES-) m/e 424, 426 [M-H]-.
4-(3-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide. Yield 40%. MS (ES-) m/e 424, 426 [M-H]-.
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide. Yield 30%. MS (ES-) m/e 435 [M-H]-.
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide. Yield 35%. MS (ES-) m/e 435 [M-H]-. 4-(4-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide. Yield 28%. MS (ES-) m/e 390 [M-H]-.
4-(3-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide. Yield 49%. MS (ES-) m/e 390 [M-H]-.
4-(4-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]- 3-thiosemicarbazide. Yield 39%. MS (ES-) m/e 428, 430 [M-H]-.
4-(3-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]- 3-thiosemicarbazide. Yield 27%. MS (ES-) m/e 428, 430 [M-H]-. 4-(4-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide. Yield 40%. MS (ES-) m/e 394 [M-H]-. 4-(3-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide. Yield 49%. MS (ES-) m/e 394 [M-H]-. 4-(4-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide. Yield 35%. MS (ES-) m/e 422 [M-H]-. 4-(3-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide. Yield 39%. MS (ES-) m/e 422 [M-H]-. 4-(4-carboxyphenyl)- 1-[ { 5-hydroxy-3-methyl- 1 -(4-methylphenyl)pyrazol-4-yl } methylene]- 3-thiosemicarbazide. Yield 31%. MS (ES-) m/e 408 [M-H]-. (Ex.# 15.29 - Compound E) 4-(3-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]- 3-thiosemicarbazide. Yield 41%. MS (ES-) m/e 408 [M-H]-. (Ex.# 15.30 - Compound F) 4-(4-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]- 3-thiosemicarbazide.Yield 29%. MS (ES-) m/e 428, 430 [M-H]-.(Ex.# 15.31 -Compound G) 4-(3-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide. Yield 21%. MS (ES-) m/e 428, 430 [M-H]-.
Example 16 - Capsule Composition An oral dosage form for administering a presently invented agonist of the TPO receptor is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table II, below.
Table II
INGREDIENTS AMOUNTS
4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2- 20 mg hydroxybenzylidene]-3-thiosemicarbazide (Compound A)
Lactose 55 mg
Talc 16 mg
Magnesium Stearate 4 mg Example 17 - Injectable Parenteral Composition An injectable form for administering a presently invented agonist of the TPO receptor is produced by stirring 1.5% by weight of 4-(3-carboxyphenyl)-l-[3-(3,4- dimethylphenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide (Compound A), in 10% by volume propylene glycol in water.
Example 18 - Tablet Composition The sucrose, calcium sulfate dihydrate and a presently invented agonist of the TPO receptor, as shown in Table III below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
Table III INGREDIENTS AMOUNTS
4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2- 20 mg hydroxybenzylidene]-3-thiosemicarbazide (Compound A) calcium sulfate dihydrate 30 mg sucrose 4 mg starch 2 mg talc 1 mg stearic acid 0.5 mg
Particularly preferred among the compounds of the present invention are the following.
4-(4-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(4-carboxyphenyl)- 1 - [2-hydroxy-3-(3-trif-uoromethylphenyl)benzylidene]-3- thiosemicarbazide;
4-(3-carboxyphenyl)- 1 - [2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide ;
4-(4-c--rboxyphenyl)-l-[3-(4-fluorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(3 -carboxyphenyl)- 1 - [3 -(4-chlorophenyl)-2-hydroxybenzylidene] -3 - thiosemicarbazide;
4-(4-carboxyphenyI)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(3-chlorophenyl)--2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazoI-4- yI}methylene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[{l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide;
4-(4-carboxypheny 1)- 1 - [ { 5-hydroxy-3-methy 1- 1 -(4-methylpheny l)pyrazol-4-yl } methylene] -
3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4- yl }methylene]-3-thiosemicarbazide; and
4-(4-carboxyphenyl)- 1 - [ { 1 -(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide.
While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

Claims

What is claimed is:
1. A method of treating of thrombocytopenia in a mammal, including a human, in need thereof which comprises administering to such mammal a therapeutically effective amount of a compound of Formula (I):
Figure imgf000028_0001
wherein:
R is aryl, optionally substituted with 1 or more substituents selected from C\- lOalkyl, aryl, heteroaryl, halogen, -C(0)OR7, -CONR7R8, -S(0)nR6, - S(0)2NR7R°, sulfonyloxy, nitro, optionally substituted amino, hydroxy, alkoxy;
R**-* is selected from hydrogen, Cj.^al yl, aryl, substituted aryl, and alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryl, substituted aryl, amino, N-acylamino, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, -C(0)OR7, -S(0)2NR7R8, -S(0)nR6, aryloxy, nitro, cyano, halogen, and protected -OH, where
R" is selected from hydrogen, alkyl, cycloalkyl, C -C 2aryl, substituted alkyl, substituted cycloalkyl and substituted C -C 2aryl, and R7 and R° are independently selected from hydrogen, cycloalkyl, aryl, substituted cycloalkyl, substituted aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -C(0)OR", -S(0)nR°, - C(0)NR6R6, -S(0)2NR6R6, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, C -C 2aryl, substituted C -C 2 ryl and protected -OH where R" is as described above; n is 0-3;
Z is selected from S or NR where R2 is as defined above;
R3 is selected from hydrogen, C -C oalkyl, phenyl, substituted phenyl, carboxyl or C i -C i Qalkoxycarbony 1 ;
L is naphthyl or a group of formula (L):
Figure imgf000029_0001
( ) where A, B, D and E independently represent CR1 or N; where R1 is selected from hydrogen, halogen, -CF3, -CN, -SO3H, -S0 Na, -S02R14, -N02, phenyl, substituted phenyl, Cχ-Cιnalkyl, Cχ-Cχnalkoxy, Cχ-Cχoacyloxy, arylalkoxy, -
COR14, -NR12R13, hydroxy or cycloalkyl; where R14 is selected from hydroxy, Ci -Cj øalkyl, phenyl, amino, mono- or dialkylamino; R12 and R13 are independently selected from hydrogen, Cχ.χoalkyl, Cχ-C 2 ryl, substituted Cχ-C 2aryl, Cχ_χoacyl or cycloalkyl; or either A=B or D=E alternatively represent O, S or NR12; where R12 is as defined above;
Y is selected from -S, -O and -NRA where R1^ is selected from hydrogen, Cj- Cχnalkyl, substituted Cι-Cχnalkyl, Cj-Cgalkylphenyl, substituted C - Cgalkylphenyl, Cχ-Cχoacyl, substituted Cχ-Cχoacyl, or SO2R , where R" is C\- CjQalkyl, substituted Cχ-C nalkyl, Cχ-C 2aryl or substituted C -C 2aryl; and
X is selected from -SR16, -OR16 or -NHR17; where R16 is hydrogen, Cx-Cxøalkyl or substituted C -Cχoalkyl; R17 is hydrogen, Cχ-Cχøalkyl, substituted Cχ-Cχoalkyl, Cχ-Cgalkylphenyl, C\-
CjQacyl or substituted C -Cχoacyl; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
2. A method of claim 1 which comprises administering a therapeutically effective amount of a compound of Formula (I) wherein:
R1 is phenyl, substituted with either carboxylic acid or sulfonic acid; Z, R-2, R3, L, X and Y are as described in claim 1; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
3. A method of claim 1 which comprises administering a therapeutically effective amount of a compound of Formula (I) wherein:
Z is NH;
R*2 and R3 are hydrogen; Y = S;
R1, L, X are as described in claim 1; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
4. A method of claim 1 which comprises administering a therapeutically effective amount of a compound of Formula (I) wherein:
L is selected from 3-biphenyl , 4-biphenyl or 1-N-phenylpyrazole substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F;
X = OH;
Z, R1, R2, R3 and Y are as described in claim 1; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
5. A method of claim 1 which comprises administering a therapeutically effective amount of a compound of Formula (II) wherein:
Figure imgf000030_0001
X is selected from 3-carboxylic acid, 4-carboxylic acid, 3-sulfonic acid or 4- sulfonic acid; W is selected from 3-phenyl or 4-phenyl; in either case substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
6. A method of claim 1 which comprises administering a therapeutically effective amount of a compound of Formula (III) wherein:
Figure imgf000031_0001
X is selected from 3-carboxylic acid, 4-carboxylic acid, 3-sulfonic acid or 4- sulfonic acid; W is N-phenyl substituted with from 1 to 3 substituents selected from the group consisting of: nitro, alkyl, substituted alkyl, Br, CI, CF3 and F; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
7. The method of claim 1 wherein the compound is selected form:
4-1 4-chloro-2-methylphenyl)-l-(3,5-dinitro-2-hydroxybenzylidene)-3-thiosemicarbazide; 1- 3,5-dinitro-2-hydroxybenzylidene)-4-(2-methylphenyl)-3-thiosemicarbazide; 1- 3,5-dichloro-2-hydroxybenzylidene)-4-(4-ethoxycarbonylphenyl)-3-thiosemicarbazide; 4-, naphth-l-yl)-l-(2,4,6-trihydroxybenzylidene)-3-thiosemicarbazide; 1- 3,5-dichloro-2-hydroxybenzylidene)-4-(4-sulfophenyl)-3-thiosemicarbazide; 1- (2-hydroxynaphth-l-yl)methylidene]-4-(4-sulfophenyl)-3-thiosemicarbazide; 4- 4-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide; 1- l-(4-carboxy-2-hydroxyphenyl)ethylidene]-4-(naphth-l-yl)-3-thiosemicarbazide; 4- 4-carboxyphenyl)-l-[(2-hydroxynaphth-l-yl)methylidene]-3-thiosemicarbazide; 4- 3-carboxyphenyl)-l-[(2-hydroxynaphth-l-yl)methylidene]-3-thiosemicarbazide; 4- 3-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide; 1- 4-carboxy-2-hydroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide; 4- 4-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide; 4- 3-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide; 1- 4-benzyloxy-2-hydroxybenzylidene)-4-(4-carboxyphenyl)-3-thiosemicarbazide; 1- 4-benzyloxy-2-hydroxybenzylidene)-4-(3-carboxyphenyl)-3-thiosemicarbazide; 4- 3-carboxyphenyl)-l-(5-chloro-2-hydroxybenzylidene)-3-thiosemicarbazide; 4- 4-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide; -(3-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide; -(4-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide; -(3-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide; -(4-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(2-hydroxy-5-methylbenzylidene)-3-thiosemicarbazide; l-(2,4-dihydroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide; l-(2-hydroxy-3-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide; -(3-chloro-2-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide; l-(2-hydroxy-4-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide;
4-(3-chloro-4-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide; l-(2-hydroxy-4-carboxybenzylidene)-4-(4-methylphenyl)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-methoxy-3-(4-methylphenyl)benzylidene]-3-thiosemicarbazide; -(3-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-methoxybenzylidene]-3- thiosemicarbazide ; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide ; 4-(3-carboxyphenyl)- 1 - [2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide; 4-(3-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; and 4-(3-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide. or pharmaceutically acceptable salts, hydrates, solvates and esters thereof.
8. A method of enhancing platelet production in a mammal, including a human, in need thereof which comprises administering to such mammal a therapeutically effective amount of a compound of Claim 1.
9. The method of claim 3 wherein the compound is a compound of in claim 2.
10. A pharmaceutical composition for use in enhancing platelet production which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.
11. Use of a compound of Formula (I), as described in claim 1 , in the manufacture of a medicament for use in treating of thrombocytopenia.
12. The method of claim 1 wherein the compound is administered orally.
13. The method of claim 1 wherein the compound is administered parenterally.
14. A method of agonizing the TPO receptor in a subject which comprises administering an effective amount of a compound as described in claim 1.
15. A compound represented by Formula (I) as described in claim 1.
16. A compound represented by Formula (I) as described in claim 2.
17. A compound represented by Formula (I) as described in claim 3.
18. A compound represented by Formula (I) as described in claim 4.
19. A compound represented by Formula (II) as described in claim 5.
20. A compound represented by Formula (III) as described in claim 6.
21. A compound of claim 15 selected from: 4-(naphth-l-yl)-l-(2,4,6-trihydroxybenzylidene)-3-thiosemicarbazide; l-(3,5-dichloro-2-hydroxybenzylidene)-4-(4-sulfophenyl)-3-thiosemicarbazide; l-[(2-hydroxynaphth-l-yl)methylidene]-4-(4-sulfophenyl)-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide;
1 - [ l-(4-carboxy-2-hydroxyphenyl)ethylidene]-4-(naphth- 1 -yl)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[(2-hydroxynaphth-l-yl)methylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[(2-hydroxynaphth-l-yl)methylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(3,5-dichloro-2-hydroxybenzylidene)-3-thiosemicarbazide; l-(4-carboxy-2-hydroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(3,5-dibromo-2-hydroxybenzylidene)-3-thiosemicarbazide; l-(4-benzyloxy-2-hydroxybenzylidene)-4-(4-carboxyphenyl)-3-thiosemicarbazide; l-(4-benzyloxy-2-hydroxybenzylidene)-4-(3-carboxyphenyl)-3-thiosemicarbazide; -(3-carboxyphenyl)-l-(5-chloro-2-hydroxybenzylidene)-3-thiosemicarbazide; -(4-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide; -(3-carboxyphenyl)-l-[(l-hydroxynaphth-2-yl)methylidene]-3-thiosemicarbazide; -(4-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide; -(3-carboxyphenyl)-l-(3,5-di-t-butyl-2-hydroxybenzylidene)-3-thiosemicarbazide; -(4-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide; -(3-carboxyphenyl)-l-(2-hydroxy-3-methylbenzylidene)-3-thiosemicarbazide; -(3-carboxyphenyl)-l-(2-hydroxy-5-methylbenzylidene)-3-thiosemicarbazide; l-(2,4-dihydroxybenzylidene)-4-(naphth-l-yl)-3-thiosemicarbazide; l-(2-hydroxy-3-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide;
4-(3-chloro-2-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide; l-(2-hydroxy-4-carboxybenzylidene)-4-(2-phenylphenyl)-3-thiosemicarbazide;
4-(3-chloro-4-methylphenyl)-l-(2-hydroxy-4-carboxybenzylidene)-3-thiosemicarbazide; l-(2-hydroxy-4-carboxybenzylidene)-4-(4-methylphenyl)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-methoxy-3-(4-methylphenyl)benzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-methoxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-methoxybenzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(2-methylphenyl)benzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide ; 4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide ; 4-(4-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(3-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyI)benzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-nitrophenyl)benzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-(2-hydroxy-4-phenylbenzylidene)-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[{l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide ; 4-(3-carboxyphenyl)-l-[{ l-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[(5-hydroxy-3-methyl-l-phenylpyrazol-4-yl)methylene]-3- thiosemicarbazide ; 4-(3-carboxyphenyl)- 1- [(5-hydroxy-3-methyl- 1-pheny lpyrazol-4-y l)methylene]-3- thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylρyrazol-4- yl}methylene]-3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylρyrazol-4- yl}methylene]-3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(3-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide; 4-(4-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide; and 4-(3-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]- 3-thiosemicarbazide .
22. A compound of claim 16 selected from: 4-(4-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide;
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide ; 4-(4-carboxyphenyl)-l-[3-(4-fluorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(dibenzo[b,d]furan-l-yl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(naphth-l-yl)benzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[3-(3-chlorophenyl)-2-hydroxybenzylidene]-3-thiosemicarbazide;
4-(4-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[{ l-(3,4-dimethylphenyl)-5-hydroxy-3-methylpyrazol-4- yl}methylene]-3~thiosemicarbazide;
4-(4-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide;
4-(3-carboxyphenyl)-l-[{5-hydroxy-3-methyl-l-(4-methylphenyl)pyrazol-4-yl}methylene]-
3-thiosemicarbazide; and
4-(4-carboxyphenyl)- 1 -[ { 1 -(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl } methylene]-
3-thiosemicarbazide.
23. A compound of claim 19 selected from: 4-(3-carboxyphenyl)-l-[3-(3,4-dimethylphenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide;
4-(4-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide ;
4-(3-carboxyphenyl)-l-[2-hydroxy-3-(3-trifluoromethylphenyl)benzylidene]-3- thiosemicarbazide; and
4-(3-carboxyphenyl)-l-[3-(4-chlorophenyl)-2-hydroxybenzylidene]-3- thiosemicarbazide.
24. A compound of claim 20 selected from:
4-(4-carboxyphenyl)- 1 - [ { 5-hydroxy-3-methyl- 1 -(4-methylphenyl)pyrazol-4-yl } methylene]-
3-thiosemicarbazide;
4-(3-carboxyphenyl)- 1 - [ { 5-hydroxy-3-methyl- 1 -(4-methylphenyl)pyrazol-4-yl Jmethylene]-
3-thiosemicarbazide; and
4-(4-carboxyphenyl)-l-[{ l-(3-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}methylene]-
3-thiosemicarbazide.
PCT/US2001/050774 2000-12-19 2001-12-19 Thrombopoietin mimetics WO2002049413A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/451,300 US7241783B2 (en) 2000-12-19 2001-12-19 Thrombopoietin mimetics
AU2002239718A AU2002239718A1 (en) 2000-12-19 2001-12-19 Thrombopoietin mimetics
JP2002550771A JP2004520302A (en) 2000-12-19 2001-12-19 Thrombopoietin mimic
EP01987514A EP1349613A4 (en) 2000-12-19 2001-12-19 Thrombopoietin mimetics
CA002436288A CA2436288A1 (en) 2000-12-19 2001-12-19 Thrombopoietin mimetics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25662200P 2000-12-19 2000-12-19
US60/256,622 2000-12-19

Publications (2)

Publication Number Publication Date
WO2002049413A2 true WO2002049413A2 (en) 2002-06-27
WO2002049413A3 WO2002049413A3 (en) 2003-01-23

Family

ID=22972928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050774 WO2002049413A2 (en) 2000-12-19 2001-12-19 Thrombopoietin mimetics

Country Status (6)

Country Link
US (1) US7241783B2 (en)
EP (1) EP1349613A4 (en)
JP (1) JP2004520302A (en)
AU (1) AU2002239718A1 (en)
CA (1) CA2436288A1 (en)
WO (1) WO2002049413A2 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078386A1 (en) * 2002-03-19 2003-09-25 Unisearch Limited Naphthylsemicarbazone, naphthylhydrazone, naphthylthiosemicarbazone, and naphthylthiohydrazone compounds and therapeutic use thereof
WO2004108683A1 (en) * 2003-06-06 2004-12-16 Nissan Chemical Industries, Ltd. 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
JP2005330204A (en) * 2004-05-19 2005-12-02 Otsuka Pharmaceut Co Ltd Megakaryocyte production-inducing agent
JP2006506452A (en) * 2002-10-09 2006-02-23 日産化学工業株式会社 Pyrazolone compounds and thrombopoietin receptor activators
WO2006062247A1 (en) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. Substituted heterocyclic compound and thrombopoietin receptor activator
WO2006062249A1 (en) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. Substituted heterocyclic compound and thrombopoietin receptor activator
US7160870B2 (en) 2000-05-25 2007-01-09 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2007142308A1 (en) 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compound and thrombopoietin receptor activator
CN100443472C (en) * 2003-06-06 2008-12-17 日产化学工业株式会社 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
US7547719B2 (en) 2002-05-22 2009-06-16 Smithkline Beecham Corp. 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
US7666857B2 (en) 2003-10-22 2010-02-23 Smithkline Beecham Corp. 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US7851503B2 (en) 2002-08-14 2010-12-14 Nissan Chemical Industries, Ltd. Thrombopoetin receptor activator and process for producing the same
US7960425B2 (en) 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
US7968542B2 (en) 2005-07-15 2011-06-28 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
US8026368B2 (en) 2005-11-07 2011-09-27 Nissan Chemical Industries, Ltd. Hydrazide compounds and thrombopoietin receptor activators
US8052995B2 (en) 2007-05-03 2011-11-08 Glaxosmithkline Llc 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US8134013B2 (en) 2004-12-14 2012-03-13 Nissan Chemical Industries, Ltd. Amide compound and thrombopoietin receptor activator
WO2012060388A1 (en) * 2010-11-02 2012-05-10 日産化学工業株式会社 Organic amine salt of aminobenzoic acid derivative, and method for producing same
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013110198A1 (en) 2012-01-27 2013-08-01 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US8552031B2 (en) 2004-12-08 2013-10-08 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
US8609693B2 (en) 2009-05-29 2013-12-17 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
US8889732B2 (en) 2009-10-23 2014-11-18 Nissan Chemical Industries, Ltd. Fused heterocyclic compounds and thrombopoietin receptor activators
US8927281B2 (en) 2008-10-30 2015-01-06 Irm Llc Method for expanding hematopoietic stem cells
US9624220B2 (en) 2010-04-01 2017-04-18 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US10647718B2 (en) 2014-04-22 2020-05-12 Universitéde Montréal Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
US10724028B2 (en) 2014-10-31 2020-07-28 Nissan Chemical Industries, Ltd. Ligand-binding fiber and cell culture substrate using said fiber

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
EP1805155B1 (en) * 2004-10-25 2010-11-03 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011262A1 (en) * 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
WO2000028987A1 (en) * 1998-11-17 2000-05-25 Smithkline Beecham Corporation Methods of treating thrombocytopenia
WO2001034585A1 (en) * 1999-11-05 2001-05-17 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE290184C (en) *
DE286580C (en) *
EP0433526A1 (en) * 1989-12-19 1991-06-26 Richter, Peter, Prof. Dr.sc.nat. Medicine for the treatment of heart-circulatory illnesses, of arrhythmics in particular
US5376451A (en) * 1990-06-29 1994-12-27 Minnesota Mining And Manufacturing Company Yellow color-formers
AU771460B2 (en) * 1999-09-24 2004-03-25 Smithkline Beecham Corporation Thrombopoietin mimetics
US6720345B1 (en) * 1999-11-05 2004-04-13 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011262A1 (en) * 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
WO2000028987A1 (en) * 1998-11-17 2000-05-25 Smithkline Beecham Corporation Methods of treating thrombocytopenia
WO2001034585A1 (en) * 1999-11-05 2001-05-17 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1349613A2 *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452874B2 (en) 2000-05-25 2008-11-18 Smithkline Beecham Corp. Thrombopoietin mimetics
US7439342B2 (en) 2000-05-25 2008-10-21 Smith Kline Beecham Corp. Thrombopoietin mimetics
US7332481B2 (en) 2000-05-25 2008-02-19 Smithkline Beecham Corporation Thrombopoietin mimetics
US7674887B2 (en) 2000-05-25 2010-03-09 Glaxosmithkline Llc Thrombopoietin mimetics
US7335649B2 (en) 2000-05-25 2008-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
US7473686B2 (en) 2000-05-25 2009-01-06 Smithkline Beecham Corp. Thrombopoietin mimetics
US7160870B2 (en) 2000-05-25 2007-01-09 Smithkline Beecham Corporation Thrombopoietin mimetics
US7790704B2 (en) 2000-05-25 2010-09-07 GlaxoSmithKline, LLC Thrombopoietin mimetics
US7648971B2 (en) 2000-05-25 2010-01-19 Smithkline Beecham Corp. Thrombopoietin mimetics
WO2003078386A1 (en) * 2002-03-19 2003-09-25 Unisearch Limited Naphthylsemicarbazone, naphthylhydrazone, naphthylthiosemicarbazone, and naphthylthiohydrazone compounds and therapeutic use thereof
US8846024B2 (en) 2002-05-22 2014-09-30 Glaxosmithkline Llc 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US7795293B2 (en) 2002-05-22 2010-09-14 Glaxosmithkline Llc 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US8088813B2 (en) 2002-05-22 2012-01-03 Glaxosmithkline Llc 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US7547719B2 (en) 2002-05-22 2009-06-16 Smithkline Beecham Corp. 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
US7851503B2 (en) 2002-08-14 2010-12-14 Nissan Chemical Industries, Ltd. Thrombopoetin receptor activator and process for producing the same
US8053453B2 (en) 2002-10-09 2011-11-08 Nissan Chemical Industries, Ltd. Pyrazolone compounds and thrombopoietin receptor activator
JP2006506452A (en) * 2002-10-09 2006-02-23 日産化学工業株式会社 Pyrazolone compounds and thrombopoietin receptor activators
US7576115B2 (en) 2003-06-06 2009-08-18 Nissan Chemical Industries, Ltd. Heterocyclic compounds and thrombopoietin receptor activators
WO2004108683A1 (en) * 2003-06-06 2004-12-16 Nissan Chemical Industries, Ltd. 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
CN100443472C (en) * 2003-06-06 2008-12-17 日产化学工业株式会社 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
US7351841B2 (en) 2003-06-06 2008-04-01 Nissan Chemical Industries, Ltd. Heterocyclic compounds and thrombopoietin receptor activators
US8318796B2 (en) 2003-06-06 2012-11-27 Nissan Chemical Industries, Ltd. Heterocyclic compounds and thrombopoietin receptor activators
TWI395739B (en) * 2003-06-06 2013-05-11 Nissan Chemical Ind Ltd Heterocyclic compounds and thrombopoietin receptor activators
JP2010006821A (en) * 2003-06-06 2010-01-14 Nissan Chem Ind Ltd Method for producing hydrazide compound
US7666857B2 (en) 2003-10-22 2010-02-23 Smithkline Beecham Corp. 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
JP2005330204A (en) * 2004-05-19 2005-12-02 Otsuka Pharmaceut Co Ltd Megakaryocyte production-inducing agent
US8552031B2 (en) 2004-12-08 2013-10-08 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
WO2006062249A1 (en) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. Substituted heterocyclic compound and thrombopoietin receptor activator
WO2006062247A1 (en) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. Substituted heterocyclic compound and thrombopoietin receptor activator
US8134013B2 (en) 2004-12-14 2012-03-13 Nissan Chemical Industries, Ltd. Amide compound and thrombopoietin receptor activator
US7968542B2 (en) 2005-07-15 2011-06-28 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
US7960425B2 (en) 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
US8026368B2 (en) 2005-11-07 2011-09-27 Nissan Chemical Industries, Ltd. Hydrazide compounds and thrombopoietin receptor activators
WO2007142308A1 (en) 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compound and thrombopoietin receptor activator
US8093251B2 (en) 2006-06-07 2012-01-10 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
US8052995B2 (en) 2007-05-03 2011-11-08 Glaxosmithkline Llc 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US8071129B2 (en) 2007-05-03 2011-12-06 Glaxosmithkline Llc 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US8062665B2 (en) 2007-05-03 2011-11-22 Glaxosmithkline Llc 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US8052994B2 (en) 2007-05-03 2011-11-08 Glaxosmithkline Llc 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US8828430B2 (en) 2007-05-03 2014-09-09 Glaxosmithkline Llc 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US8052993B2 (en) 2007-05-03 2011-11-08 Glaxosmithkline Llc 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US8927281B2 (en) 2008-10-30 2015-01-06 Irm Llc Method for expanding hematopoietic stem cells
US9580426B2 (en) 2008-10-30 2017-02-28 Novartis Ag Compounds that expand hematopoietic stem cells
EP3524604A1 (en) 2008-10-30 2019-08-14 Novartis AG Expanded hematopoietic stem cells from cord blood and their therapeutic use
US8609693B2 (en) 2009-05-29 2013-12-17 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
US8889732B2 (en) 2009-10-23 2014-11-18 Nissan Chemical Industries, Ltd. Fused heterocyclic compounds and thrombopoietin receptor activators
US9624220B2 (en) 2010-04-01 2017-04-18 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8946286B2 (en) 2010-11-02 2015-02-03 Nissan Chemical Industries, Ltd. Organic amine salts of aminobenzoic acid derivatives and method for producing same
RU2569885C2 (en) * 2010-11-02 2015-12-10 Ниссан Кемикал Индастриз, Лтд. Organic amine salts of aminobenzoic acid and method for obtaining thereof
JP5892069B2 (en) * 2010-11-02 2016-03-23 日産化学工業株式会社 Organic amine salt of aminobenzoic acid derivative and process for producing the same
WO2012060388A1 (en) * 2010-11-02 2012-05-10 日産化学工業株式会社 Organic amine salt of aminobenzoic acid derivative, and method for producing same
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
US9834755B2 (en) 2011-12-08 2017-12-05 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013110198A1 (en) 2012-01-27 2013-08-01 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US10336747B2 (en) 2012-01-27 2019-07-02 Université de Montréal Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US9409906B2 (en) 2012-01-27 2016-08-09 Universite De Montreal Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US10647718B2 (en) 2014-04-22 2020-05-12 Universitéde Montréal Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
US10724028B2 (en) 2014-10-31 2020-07-28 Nissan Chemical Industries, Ltd. Ligand-binding fiber and cell culture substrate using said fiber

Also Published As

Publication number Publication date
AU2002239718A1 (en) 2002-07-01
EP1349613A2 (en) 2003-10-08
JP2004520302A (en) 2004-07-08
EP1349613A4 (en) 2005-09-21
WO2002049413A3 (en) 2003-01-23
US7241783B2 (en) 2007-07-10
CA2436288A1 (en) 2002-06-27
US20040058990A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
EP1349613A2 (en) Thrombopoietin mimetics
AU771460B2 (en) Thrombopoietin mimetics
AU770564B2 (en) Thrombopoietin mimetics
WO2001034585A1 (en) Semicarbazone derivatives and their use as thrombopoietin mimetics
US6670387B1 (en) Thrombopoietin mimetics
US6498155B1 (en) Methods of treating thrombocytopenia
EP1864981B1 (en) Thrombopoietin mimetics
DE60031714T2 (en) Thrombopoietin mimetics
EP1370252A1 (en) Thrombopoietin mimetics
US6720345B1 (en) Semicarbazone derivatives and their use as thrombopoietin mimetics
US6858630B2 (en) Naphthimidazole derivatives and their use as thrombopoietin mimetics
US6875786B2 (en) Thrombopoietin mimetics
US6642265B1 (en) Thrombopoietin mimetics
WO2009151862A1 (en) Method of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002239718

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2436288

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10451300

Country of ref document: US

Ref document number: 2002550771

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001987514

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001987514

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642